Background GLP-1 receptor agonists (GLP-1 RAs) with exenatide bid first approved to treat
type 2 diabetes in 2005 have been further developed to yield effective compounds …

Importance Approximately 125 million people worldwide have psoriasis. Patients with
psoriasis experience substantial morbidity and increased rates of inflammatory arthritis …

Background: Psoriasis is a common, chronic, inflammatory, debilitating, systemic disease
with a great impact on healthcare systems worldwide. As targeted therapies have …

Research on psoriasis pathogenesis has largely increased knowledge on skin biology in
general. In the past 15 years, breakthroughs in the understanding of the pathogenesis of …

Background Risankizumab is a humanised IgG1 monoclonal antibody that binds to the p19
subunit of interleukin-23, inhibiting this key cytokine and its role in psoriatic inflammation …

Abstract Evaluation of coronary artery disease (CAD) using coronary computed tomography
angiography (CCTA) has seen a paradigm shift in the last decade. Evidence increasingly …

Background Psoriasis is a chronic, systemic immune‐mediated disease characterized by
development of erythematous, indurated, scaly, pruritic and often painful skin plaques …

Psoriasis is a common chronic inflammatory disease of the skin that is increasingly being
recognized as a systemic inflammatory disorder. Psoriatic arthritis is a well-known …

Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with
awareness and attention to comorbidities - ScienceDirect Skip to main contentSkip to article …

Psoriasis is one of the most common chronic inflammatory skin diseases, affecting 3% of the
world's population, and approximately one-third of patients with psoriasis will eventually …